Impact of octreotide LAR on tumour growth control as first-line treatment in neuroendocrine tumours of pancreatic origin
Jann H et al. – The aim of the investigation was to evaluate the antiproliferative effect of Somatostatin analogues (SSA) in patients with pancreatic neuroendocrine tumours (NET). SSA may be considered as first–line treatment for antiproliferative purposes in metastatic NET of the pancreas. Patients with a proliferation index of less than 10% displayed a more durable response compared to those with a higher proliferation index.